Abstract 566P
Background
The CinClare phase III study (NCT02605265) demonstrated that the addition of irinotecan to capecitabine in combination with radiotherapy significantly increased the pathologic complete response(pCR) rate in locally advanced rectal cancer (LARC). However, it was not well tolerated among some patients, who failed to complete their planned weekly irinotecan chemotherapy. This study is a post-hoc analysis of the CinClare study designed to assess the impact of irinotecan chemotherapy completion in preoperative chemoradiotherapy on efficacy, toxicity, and long-term survival.
Methods
Patients were categorized into three groups based on the cycles of weekly irinotecan they actually received in the CinClare study. Group A received only capecitabine, while Group B and C actually received 1-3 or 4-5 cycles of weekly irinotecan during the course of chemoradiotherapy, respectively. Tumor response, toxicity, and long-term survival were compared among the three groups.
Results
A total of 356 patients were included in the analysis. The pCR rates were 17.4%, 20.8%, and 38.4% in Groups A, B, and C, respectively (P < 0.001). Grade 3-4 adverse events were 6.2%,52.8%,32.0% respectively. The 5-year DFS and OS rates in Groups A, B, and C were 70.6% vs. 76.9% vs. 78.1% and 76.1% vs. 80.0% vs. 84.2%, respectively.
Conclusions
The administration of 4-5 cycles of weekly irinotecan in preoperative chemoradiotherapy was significantly associated with better tumor response and showed a trend toward beneficial DFS and OS in patients with LARC.
Clinical trial identification
NCT02605265.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
556P - Predicting the efficacy of neoadjuvant chemoradiotherapy in rectal cancer patients based on dynamic tumor-informed ctDNA-MRD
Presenter: Weiwei Xiao
Session: Poster session 16
557P - Three-year update of real-world evaluation of ColonAiQ for colorectal cancer screening in asymptomatic individuals
Presenter: Baohua Wang
Session: Poster session 16
558P - Survival benefit of adjuvant chemotherapy based on molecular residual disease detection in resected colorectal liver metastases: Subgroup analysis from CIRCULATE-Japan GALAXY
Presenter: Kozo Kataoka
Session: Poster session 16
561P - Liquid biopsy tracking of immunotherapy-induced T cell dynamics in MSS colorectal and endometrial tumors
Presenter: Holger Heyn
Session: Poster session 16
562P - Acquired genomic alterations on first-line chemotherapy (CT) + cetuximab in advanced colorectal cancer (mCRC): Circulating tumor (ct)DNA analysis of the randomized phase II trial TIME-PRODIGE-28
Presenter: Valerie Boige
Session: Poster session 16
564P - Short-course radiotherapy combined with chemotherapy and PD-1 inhibitor in proficient mismatch repair or microsatellite stable (pMMR/MSS) low-lying early rectal cancer: Preliminary findings from a prospective, multi-center, phase II trial (TORCH-E)
Presenter: Fan Xia
Session: Poster session 16
565P - Neoadjuvant chemotherapy, excision, and observation for early rectal cancer: The phase II NEO trial (CCTG CO.28) results after minimum 3 years follow up
Presenter: Carl Brown
Session: Poster session 16